Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierProtagonist Therapeutics, Inc. (referred to as “Protagonist,” the “Company,” “we,” “our” or “us”) is an integrated discovery and development company with a validated technology platform. Our programs fall into three broad therapeutic areas: (i) inflammation and immunology (“I&I”), (ii) hematology and (iii) metabolic diseases. Our aim is to develop medicines for biologically and commercially validated targets which demonstrate a strong differentiation compared to existing therapies.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Protagonist Therapeutics, Inc. (PTGX) reported revenue of $213M in Q2 2026 (quarter ended June 30, 2026), up 3749% from the same quarter a year earlier. That came with net income of $163M (76% of revenue). For the full year FY2025, revenue was $46M (−89% year on year) and net income −$130M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.